Sangamo Therapeutics, Inc.
7000 Marina Blvd
Brisbane
CA
94005
United States
Tel: (510) 970-6000
Website: https://www.sangamo.com/
Email: hr@sangamo.com
About Sangamo Therapeutics, Inc.
Sangamo Therapeutics is a genomic medicine company building value with cutting-edge work across four distinct but complementary technology platforms – gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. At Sangamo, we are passionate in developing genomic medicines to transform the lives of patients with serious diseases. We transform lives by building a robust, sustainable, differentiated, innovative, and high value genomic medicine pipeline that addresses patients with life-limiting conditions. Sangamo takes pride in being the first to edit endogenous human genes, first to treat patients with gene edited T cells, and first to treat patients with in vivo genome editing. Our top priority is to meet the needs of patients with commitment and compassion. Along with our commitment to science and to our patients, we also endeavor to create an inclusive environment that promotes and values diversity. Sangamo is a company where individuals can flourish, grow and develop their expertise.
We are seeking top talent to join our mission. Let’s build a better future together.
Stock Symbol: SGMO
634 articles about Sangamo Therapeutics, Inc.
-
Sangamo BioSciences, Inc. Reports Second Quarter 2010 Financial Results
7/29/2010
-
Sangamo BioSciences, Inc. Announces Second Quarter 2010 Conference Call and Webcast
7/22/2010
-
Sangamo BioSciences, Inc. Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
7/6/2010
-
Sangamo BioSciences, Inc. Receives The Michael J. Fox Foundation Funding to Develop Novel Drug for the Treatment of Parkinson's Disease
7/1/2010
-
Sangamo BioSciences, Inc. Presents Positive Phase 2 ZFP Therapeutic Data From SB-509 Programs in Diabetic Neuropathy at American Diabetes Association 2010
6/29/2010
-
Sangamo BioSciences, Inc. Announces Presentation at Two Upcoming Investor Conferences
6/4/2010
-
Sangamo BioSciences, Inc. and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
5/24/2010
-
Sangamo BioSciences, Inc. Announces Presentation at Two Upcoming Investor Conferences
5/5/2010
-
Sangamo BioSciences, Inc. Reports First Quarter 2010 Financial Results
5/4/2010
-
Sangamo BioSciences, Inc. Announces First Quarter 2010 Conference Call and Webcast
4/27/2010
-
Sangamo BioSciences, Inc. Appoints William R. Ringo as Chairman of the Board of Directors
4/19/2010
-
Sangamo BioSciences, Inc. Appoints Dr. Stephen G. Dilly to Its Board of Directors
4/1/2010
-
Sangamo BioSciences, Inc. Announces Presentation at Cowen and Company Health Care Conference
3/4/2010
-
Sangamo BioSciences, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results Company Ends Year with Cash and Investments of $85.3 Million
2/4/2010
-
Sangamo BioSciences, Inc. Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast
1/28/2010
-
Sangamo BioSciences, Inc. Announces Presentation of Preliminary Data From Phase 1 Safety Trial of SB-728-T for HIV/AIDS First Human Data from ZFN Clinical Program ZFN-Modified Cells Well Tolerated and Able to Expand
1/19/2010
-
Sangamo BioSciences, Inc. Advances ZFP Therapeutic(TM) Pipeline
1/11/2010
-
Sangamo BioSciences, Inc. Announces Presentation at J.P. Morgan Healthcare Conference
1/7/2010
-
Sangamo BioSciences, Inc. Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium Early Data Demonstrates Improvement in Muscle Function with SB-509 Treatment Compared to Historic Controls
12/9/2009
-
Sangamo BioSciences, Inc. Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium Early Data Demonstrates Improvement in Muscle Function with SB-509 Treatment Compared to Historic Controls
12/9/2009